Bristol-Myers Squibb cuts 2026 adjusted EPS forecast to $6.35-$6.55
- Bristol-Myers Squibb raised 2026 revenue guidance to $49.75 billion-$50.25 billion from $49 billion-$50 billion.
- Adjusted diluted earnings guidance fell to $6.35-$6.55 per share from $6.75-$7, incorporating a $0.58 third-quarter acquisition-related research and licensing impact.
- The higher revenue outlook reflects year-to-date strength, including continued Growth Portfolio momentum; third-quarter portfolio revenue rose 12% to $7.7 billion.
- Legacy Portfolio revenue is expected to decline 3%-5%, with worldwide Eliquis revenue forecast to grow 20%-25%.
- Gross margin guidance remained approximately 69%-70%; operating expenses are still projected at approximately $16.5 billion.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.